Related Experiment Video
Updated: Apr 15, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Marine natural products as breast cancer resistance protein inhibitors
Lilia Cherigo1, Dioxelis Lopez2,3, Sergio Martinez-Luis4
1Department of Organic Chemistry, Chemistry School, Faculty of Natural Sciences, Exact and Technology, University of Panama, Panama City P.O. Box 3366, Panama. chery826@hotmail.com.
Abstract:
Breast cancer resistance protein (BCRP) is a protein belonging to the ATP-binding cassette (ABC) transporter superfamily that has clinical relevance due to its multi-drug resistance properties in cancer. BCRP can be associated with clinical cancer drug resistance, in particular acute myelogenous or acute lymphocytic leukemias. The overexpression of BCRP contributes to the resistance of several chemotherapeutic drugs, such as topotecan, methotrexate, mitoxantrone, doxorubicin and daunorubicin. The Food and Drugs Administration has already recognized that BCRP is clinically one of the most important drug transporters, mainly because it leads to a reduction of clinical efficacy of various anticancer drugs through its ATP-dependent drug efflux pump function as well as its apparent participation in drug resistance. This review article aims to summarize the different research findings on marine natural products with BCRP inhibiting activity. In this sense, the potential modulation of physiological targets of BCRP by natural or synthetic compounds offers a great possibility for the discovery of new drugs and valuable research tools to recognize the function of the complex ABC-transporters.
Insights
Marine natural products show potential for inhibiting breast cancer resistance protein (BCRP), a key factor in cancer drug resistance. This research explores compounds that could overcome chemotherapy resistance and aid in developing new cancer therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Breast cancer resistance protein (BCRP) is an ATP-binding cassette (ABC) transporter implicated in multidrug resistance (MDR) in various cancers.
- BCRP overexpression reduces the efficacy of critical chemotherapeutic agents like topotecan, methotrexate, and doxorubicin.
- The U.S. Food and Drug Administration recognizes BCRP as a clinically significant transporter contributing to reduced anticancer drug effectiveness.
Purpose of the Study:
- To review and summarize research on marine natural products exhibiting BCRP inhibitory activity.
- To explore the potential of these natural compounds in overcoming BCRP-mediated drug resistance.
- To highlight the discovery of novel therapeutic agents and research tools for understanding ABC transporters.
Main Methods:
- Literature review of scientific research findings.
- Analysis of studies investigating marine natural products and their interaction with BCRP.
- Synthesis of data on BCRP's role in drug resistance and potential inhibition strategies.
Main Results:
- Identification of various marine natural products with demonstrated BCRP inhibitory effects.
- Evidence suggesting that these compounds can modulate BCRP's efflux pump function.
- Potential for these natural products to restore sensitivity to chemotherapeutic drugs.
Conclusions:
- Marine natural products represent a promising source for developing novel BCRP inhibitors.
- Targeting BCRP with natural compounds offers a viable strategy to combat cancer multidrug resistance.
- Further research into these compounds can lead to new anticancer drugs and tools for transporter research.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

